Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
REVLIMID®
.
Show all posts
Showing posts with label
REVLIMID®
.
Show all posts
Tuesday, July 30, 2013
Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma
›
In continuation of my update on lenalidomide Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: C...
›
Home
View web version
